Gilead Sciences, Inc. (NASDAQ: GILD) reported Q4 EPS of $0.55, $0.05 better than the analyst estimate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Earnings Guidance

Goldman Sachs Comments on Gilead Sciences (GILD)February 5, 2014 10:49 AM Summer Street Affirms Netural Rating on Gilead (GILD); Early Sovoldi Buy-In May Produce Softer ResultsFebruary 5, 2014 9:35 AM Gilead Sciences (GILD) Target Lifted to $101 at Maxim GroupFebruary 5, 2014 9:18 AM Gilead Sciences (GILD) Target Lifted at Needham & Company Post Q4February 5, 2014 6:52 AM